Notice2021-21845
Prospective Grant of an Exclusive Patent License: Personalized Tumor Vaccine and Use Thereof for Cancer Immunotherapy
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
October 6, 2021
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the (U.S.) Patents and Patent Applications listed in the Supplementary Information section of this notice to NE1 Inc, located at 515 Madison Avenue, 8th Fl. Suite 8096, New York, NY 10022.
Full Text
<html>
<head>
<title>Federal Register, Volume 86 Issue 191 (Wednesday, October 6, 2021)</title>
</head>
<body><pre>
[Federal Register Volume 86, Number 191 (Wednesday, October 6, 2021)]
[Notices]
[Page 55625]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-21845]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Personalized
Tumor Vaccine and Use Thereof for Cancer Immunotherapy
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute, an institute of the National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an Exclusive Patent License to practice the
inventions embodied in the (U.S.) Patents and Patent Applications
listed in the Supplementary Information section of this notice to NE1
Inc, located at 515 Madison Avenue, 8th Fl. Suite 8096, New York, NY
10022.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before October 21, 2021 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated an Exclusive Patent License
should be directed to: Dr. Berna Uygur, Technology Transfer Manager,
NCI Technology Transfer Center, Telephone: (240)-276-5530; Email:
<a href="/cdn-cgi/l/email-protection#3b595e49555a154e425c4e497b555253155c544d"><span class="__cf_email__" data-cfemail="600205120e014e1519071512200e09084e070f16">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
Intellectual Property
(United States Provisional) Patent Application No. 62/946,934,
filed on December 11, 2019 and entitled ``Personalized Tumor Vaccine
and Use Thereof for Cancer Immunotherapy'' [HHS Reference No. E-003-
2020/0-US-01]. (PCT) Patent Application No. PCT/US2020/064412, filed on
December 11, 2020 and entitled ``Personalized Tumor Vaccine and Use
Thereof for Cancer Immunotherapy'' [HHS Reference No. E-003-2020/0-PCT-
02].
The patent rights in this invention are co-owned by (a) the United
States of America, as represented by the Secretary, Department of
Health and Human Services, (b) University of South Bohemia, and (c) NE1
Inc. The prospective exclusive license territory may be worldwide, and
the field of use may be limited to: Development, manufacture, and
commercialization of the MBTA Therapy Products, as claimed in the
Licensed Patent Rights, for the treatment of cancer in humans.
This technology discloses ``MBTA Therapy Product(s)'' which are
vaccine products comprising irradiated tumor cells pulsed with
phagocytic agonists (Mannan-BAM, a polysaccharide derivative of
mannan), TLR (Toll-like receptor) ligands, and Anti-CD40-monoclonal
antibody. The MBTA Therapy Products may be used as personalized tumor
vaccines to treat cancer.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the National
Cancer Institute receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: October 1, 2021.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2021-21845 Filed 10-5-21; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on October 6, 2021.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.